JPMorgan on Thursday shared updated thoughts on Ultragenyx Pharmaceutical Inc’s (NASDAQ:RARE) setrusumab program in osteogenesis imperfecta (OI).In a fourth-quarter 2024 press release, the company said patients continue dosing in the Phase 3 Orbit and Cosmic trials, which evaluate setrusumab in pediatric and young adult patients with OI.The randomized, placebo-controlled Phase 3 portion of the Orbit study is progressing toward the second interim analysis in mid-2025 or a final analysis in the fourth quarter of 2025.Also Read: Ultragenyx’s Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid UpsidePatients in the Cosmic study continue to be treated with either setrusumab or intravenous bisphosphonates (IV-BP) therapy and will be evaluated in parallel with the Orbit interim and final analyses.JPMorgan analyst Anupam Rama said Thursday, “Ultragenyx remains on the J.P. …Full story available on Benzinga.com
Source :
For further details, visit: https://www.benzinga.com/general/biotech/25/03/44523017/ultragenyx-is-uniquely-positioned-in-long-term-remains-on-jpmorgans-focus-list
